Research programme: musculoskeletal disorders therapies - Millenium Biologix Corporation

Drug Profile

Research programme: musculoskeletal disorders therapies - Millenium Biologix Corporation

Alternative Names: ACTES™-B implants - Millenium Biologix Corporation; ACTES™-C implants - Millenium Biologix Corporation

Latest Information Update: 02 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millenium Biologix Corporation
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements; Intercellular signalling peptide and protein stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cartilage disorders; Musculoskeletal disorders

Most Recent Events

  • 06 Oct 2005 Early research in Cartilage disorders in Canada (Parenteral)
  • 06 Oct 2005 Early research in Musculoskeletal disorders in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top